Elutia Inc. (ELUT) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ELUT Revenue Growth
Revenue Breakdown (FY 2024)
ELUT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
ELUT Revenue Analysis (2018–2025)
As of May 8, 2026, Elutia Inc. (ELUT) generated trailing twelve-month (TTM) revenue of $12.3 million, reflecting significant decline in growth of -160.8% year-over-year. The most recent quarter (Q4 2025) recorded $-3,323,000 in revenue, down 200.0% sequentially.
Looking at the longer-term picture, ELUT's 5-year compound annual growth rate (CAGR) stands at -22.0%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $47.4 million in 2021.
Revenue diversification analysis shows ELUT's business is primarily driven by Women's Health (80%), and Cardiovascular (20%). With over half of revenue concentrated in Women's Health, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVCR (+8.5% YoY), XTNT (+16.9% YoY), and OSBC, ELUT has underperformed the peer group in terms of revenue growth. Compare ELUT vs NVCR →
ELUT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ELUTCurrent | $12M | -160.8% | -22.0% | -149.8% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 XTNT | $117M | +16.9% | +12.6% | -10.3% | |
 OSBC | $397M | - | - | 27.9% | |
 LMAT | $250M | +13.3% | +14.0% | 27.2% | |
 MDT | $33.5B | +6.9% | +3.0% | 17.8% |
ELUT Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $12.3M | -49.6% | $6.6M | 53.7% | $-18,412,000 | -149.8% |
| 2024 | $24.4M | -1.5% | $10.7M | 43.9% | $-35,651,000 | -146.3% |
| 2023 | $24.7M | +3.8% | $11.1M | 44.7% | $-30,526,000 | -123.4% |
| 2022 | $23.8M | -49.7% | $11.6M | 48.8% | $-35,189,000 | -147.5% |
| 2021 | $47.4M | +11.0% | $19.0M | 40.1% | $-23,032,000 | -48.6% |
| 2020 | $42.7M | -0.5% | $20.6M | 48.2% | $-13,599,000 | -31.9% |
| 2019 | $42.9M | +9.9% | $19.8M | 46.1% | $-8,409,000 | -19.6% |
| 2018 | $39.0M | - | $15.9M | 40.8% | $-8,221,000 | -21.1% |
See ELUT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELUT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELUT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELUT — Frequently Asked Questions
Quick answers to the most common questions about buying ELUT stock.
Is ELUT's revenue growth accelerating or slowing?
ELUT revenue declined -160.8% year-over-year, contrasting with the 5-year CAGR of -22.0%. TTM revenue fell to $12M. This reverses the prior growth trend.
What is ELUT's long-term revenue growth rate?
Elutia Inc.'s 5-year revenue CAGR of -22.0% reflects the variable expansion pattern. Current YoY growth of -160.8% is below this long-term average.
How is ELUT's revenue distributed by segment?
ELUT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.